New RSV vaccine trial aims to protect women from respiratory virus
NCT ID NCT07492706
First seen Apr 08, 2026 · Last updated Jun 13, 2026 · Updated 11 times
Summary
This early-stage study tests a new vaccine (MKK900) designed to protect against respiratory syncytial virus (RSV). It involves 120 healthy women aged 18 to 49. The main goal is to check the vaccine's safety and how well it triggers an immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emeritus Research Camberwell
Camberwell, Victoria, 3124, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Emeritus Research Sydney
Botany, New South Wales, 2019, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.